Palvella Therapeutics Appoints Kent Taylor as Senior Vice President of Sales for U.S. Launch of QTORIN Rapamycin

Palvella Therapeutics has appointed Kent Taylor as Senior Vice President of Sales. Taylor has a strong track record launching high-profile therapies, most recently leading U.S. sales efforts for ZORYVE at Arcutis Biotherapeutics. He will lead Palvella's U.S. sales organization in preparation for the potential U.S. launch of QTORIN for microcystic lymphatic malformations, a serious, rare, lifelong genetic disease affecting an estimated 30,000 patients in the U.S.